Trial Profile
Study of PPAR-gamma activating effect of angiotensin II receptor antagonist, telmisartan
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2021
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Olmesartan medoxomil
- Indications Hypertension
- Focus Pharmacodynamics
- 12 May 2016 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2014 New trial record